Last reviewed · How we verify
Methergine (methylergometrine)
Methergine (generic name: methylergometrine) is a Ergot Derivative drug developed by Edison Theraps Llc. It is currently FDA-approved (first approved 1946) for Postabortal Hemorrhage, Postpartum hemorrhage.
Methylergometrine (Methergine), marketed by Edison Theraps LLC, is a postabortal hemorrhage treatment that activates the 5-hydroxytryptamine receptor 2A to induce vasoconstriction. Its key strength lies in its well-established mechanism of action and a strong patent protection until 2028. The primary risk is the presence of multiple off-patent competitors with similar mechanisms of action, such as amitriptyline and amoxapine, which may limit market share and pricing power.
At a glance
| Generic name | methylergometrine |
|---|---|
| Sponsor | Edison Theraps Llc |
| Drug class | Ergot Derivative |
| Target | 5-hydroxytryptamine receptor 2A |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1946 |
Approved indications
- Postabortal Hemorrhage
- Postpartum hemorrhage
Common side effects
- Hypertension
- Hypotension
- Nausea
- Vomiting
- Acute myocardial infarction
- Transient chest pains
- Arterial spasm (coronary and peripheral)
- Bradycardia
- Tachycardia
- Dyspnea
- Hematuria
- Thrombophlebitis
Drug interactions
- amprenavir
- conivaptan
- mibefradil
- nefazodone
- nelfinavir
Key clinical trials
- Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy (NA)
- Cooling the Uterus in C-section After Dysfunctional Labor (NA)
- Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (NA)
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial (PHASE4)
- Prophylactic Methylergonovine for Twin Cesarean (PHASE4)
- Oxytocin Bolus Versus Infusion in Elective Cesarean Section" (PHASE4)
- Misoprostol Versus Active Management of Labour in CS (PHASE1)
- Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methergine CI brief — competitive landscape report
- Methergine updates RSS · CI watch RSS
- Edison Theraps Llc portfolio CI
Frequently asked questions about Methergine
What is Methergine?
What is Methergine used for?
Who makes Methergine?
What is the generic name of Methergine?
What drug class is Methergine in?
When was Methergine approved?
What development phase is Methergine in?
What are the side effects of Methergine?
What does Methergine target?
Related
- Drug class: All Ergot Derivative drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 2A
- Manufacturer: Edison Theraps Llc — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Postabortal Hemorrhage
- Indication: Drugs for Postpartum hemorrhage
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing